Commonly used criteria for response evaluation during cancer treatment
**Core Concept**
The evaluation of response to cancer treatment is a crucial aspect of oncology, allowing healthcare providers to assess the effectiveness of therapy and make informed decisions about treatment continuation or modification. This evaluation is typically based on standardized criteria that account for changes in tumor size, symptoms, and quality of life.
**Why the Correct Answer is Right**
The most commonly used criteria for response evaluation are the Response Evaluation Criteria In Solid Tumors (RECIST). Introduced in 2000 and updated in 2009 and 2017, RECIST provide a standardized framework for assessing the response of solid tumors to treatment. These criteria focus on measurable lesions, such as those visible on imaging studies like CT or MRI scans, and use size criteria to determine response. A decrease in the sum of the longest diameters of target lesions by at least 30% is considered a partial response.
**Why Each Wrong Option is Incorrect**
**Option A:** WHO criteria are used for evaluating response in hematological malignancies, not solid tumors. WHO criteria emphasize the evaluation of blood counts, bone marrow examination, and symptoms to assess response.
**Option B:** The Eastern Cooperative Oncology Group (ECOG) Performance Status is a measure of a patient's overall health and functional ability, but it is not a response evaluation criterion.
**Option C:** The European Society for Medical Oncology (ESMO) criteria are not a widely recognized or standardized response evaluation framework.
**Clinical Pearl / High-Yield Fact**
When evaluating response to cancer treatment, it's essential to use a standardized framework, such as RECIST, to ensure consistency and accuracy in assessing treatment efficacy.
**Correct Answer: C. RECIST**